Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease

Cynthia M Stonnington, Brian Harel, Dona E Locke, Joseph G. Hentz, Nan Zhang, Paul Maruff, Richard John Caselli

Research output: Contribution to journalArticle

Abstract

INTRODUCTION:: This study set out to clarify the differential acute cognitive impact of lorazepam based on varying genetic risk for Alzheimer disease. METHODS:: Fifty-seven cognitively unimpaired individuals aged 51 to 88, genotyped according to apolipoprotein E (APOE) and translocase of outer mitochondrial membrane (40 homolog) poly-T lengths, completed cognitive testing before, 2.5 and 5 hours after receiving a 1 mg dose of lorazepam. RESULTS:: Post-lorazepam, there were significant (P<0.05) declines from baseline in memory, psychomotor processing speed, and executive function. At 2.5 hours, the magnitude of this lorazepam-induced cognitive change was significantly greater in the APOE3/4 group than in the APOE3/3 group for tests of working memory and visuospatial memory/executive function. At 5 hours postchallenge, verbal memory and working memory deficits persisted in the APOE3/4 group compared with the APOE3/3 group. At 5 hours after lorazepam challenge, as compared with the very long/very long group, the short/short group performed slightly worse on a test of working memory (P<0.05), but no other differences were observed among translocase of the outer mitochondrial membrane 40 homolog poly-T variant groups. DISCUSSION:: The lorazepam challenge may be unmasking presymptomatic cognitive dysfunction associated with APOE4 carriage.

Original languageEnglish (US)
JournalAlzheimer Disease and Associated Disorders
DOIs
StateAccepted/In press - Jun 2 2017

Fingerprint

Lorazepam
Alzheimer Disease
Short-Term Memory
Poly T
Executive Function
Mitochondrial Membranes
Memory Disorders
Apolipoproteins E

ASJC Scopus subject areas

  • Clinical Psychology
  • Gerontology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease. / Stonnington, Cynthia M; Harel, Brian; Locke, Dona E; Hentz, Joseph G.; Zhang, Nan; Maruff, Paul; Caselli, Richard John.

In: Alzheimer Disease and Associated Disorders, 02.06.2017.

Research output: Contribution to journalArticle

@article{3e7ae746008c4df8b58b975686fa8b04,
title = "Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease",
abstract = "INTRODUCTION:: This study set out to clarify the differential acute cognitive impact of lorazepam based on varying genetic risk for Alzheimer disease. METHODS:: Fifty-seven cognitively unimpaired individuals aged 51 to 88, genotyped according to apolipoprotein E (APOE) and translocase of outer mitochondrial membrane (40 homolog) poly-T lengths, completed cognitive testing before, 2.5 and 5 hours after receiving a 1 mg dose of lorazepam. RESULTS:: Post-lorazepam, there were significant (P<0.05) declines from baseline in memory, psychomotor processing speed, and executive function. At 2.5 hours, the magnitude of this lorazepam-induced cognitive change was significantly greater in the APOE3/4 group than in the APOE3/3 group for tests of working memory and visuospatial memory/executive function. At 5 hours postchallenge, verbal memory and working memory deficits persisted in the APOE3/4 group compared with the APOE3/3 group. At 5 hours after lorazepam challenge, as compared with the very long/very long group, the short/short group performed slightly worse on a test of working memory (P<0.05), but no other differences were observed among translocase of the outer mitochondrial membrane 40 homolog poly-T variant groups. DISCUSSION:: The lorazepam challenge may be unmasking presymptomatic cognitive dysfunction associated with APOE4 carriage.",
author = "Stonnington, {Cynthia M} and Brian Harel and Locke, {Dona E} and Hentz, {Joseph G.} and Nan Zhang and Paul Maruff and Caselli, {Richard John}",
year = "2017",
month = "6",
day = "2",
doi = "10.1097/WAD.0000000000000200",
language = "English (US)",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease

AU - Stonnington, Cynthia M

AU - Harel, Brian

AU - Locke, Dona E

AU - Hentz, Joseph G.

AU - Zhang, Nan

AU - Maruff, Paul

AU - Caselli, Richard John

PY - 2017/6/2

Y1 - 2017/6/2

N2 - INTRODUCTION:: This study set out to clarify the differential acute cognitive impact of lorazepam based on varying genetic risk for Alzheimer disease. METHODS:: Fifty-seven cognitively unimpaired individuals aged 51 to 88, genotyped according to apolipoprotein E (APOE) and translocase of outer mitochondrial membrane (40 homolog) poly-T lengths, completed cognitive testing before, 2.5 and 5 hours after receiving a 1 mg dose of lorazepam. RESULTS:: Post-lorazepam, there were significant (P<0.05) declines from baseline in memory, psychomotor processing speed, and executive function. At 2.5 hours, the magnitude of this lorazepam-induced cognitive change was significantly greater in the APOE3/4 group than in the APOE3/3 group for tests of working memory and visuospatial memory/executive function. At 5 hours postchallenge, verbal memory and working memory deficits persisted in the APOE3/4 group compared with the APOE3/3 group. At 5 hours after lorazepam challenge, as compared with the very long/very long group, the short/short group performed slightly worse on a test of working memory (P<0.05), but no other differences were observed among translocase of the outer mitochondrial membrane 40 homolog poly-T variant groups. DISCUSSION:: The lorazepam challenge may be unmasking presymptomatic cognitive dysfunction associated with APOE4 carriage.

AB - INTRODUCTION:: This study set out to clarify the differential acute cognitive impact of lorazepam based on varying genetic risk for Alzheimer disease. METHODS:: Fifty-seven cognitively unimpaired individuals aged 51 to 88, genotyped according to apolipoprotein E (APOE) and translocase of outer mitochondrial membrane (40 homolog) poly-T lengths, completed cognitive testing before, 2.5 and 5 hours after receiving a 1 mg dose of lorazepam. RESULTS:: Post-lorazepam, there were significant (P<0.05) declines from baseline in memory, psychomotor processing speed, and executive function. At 2.5 hours, the magnitude of this lorazepam-induced cognitive change was significantly greater in the APOE3/4 group than in the APOE3/3 group for tests of working memory and visuospatial memory/executive function. At 5 hours postchallenge, verbal memory and working memory deficits persisted in the APOE3/4 group compared with the APOE3/3 group. At 5 hours after lorazepam challenge, as compared with the very long/very long group, the short/short group performed slightly worse on a test of working memory (P<0.05), but no other differences were observed among translocase of the outer mitochondrial membrane 40 homolog poly-T variant groups. DISCUSSION:: The lorazepam challenge may be unmasking presymptomatic cognitive dysfunction associated with APOE4 carriage.

UR - http://www.scopus.com/inward/record.url?scp=85020204433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020204433&partnerID=8YFLogxK

U2 - 10.1097/WAD.0000000000000200

DO - 10.1097/WAD.0000000000000200

M3 - Article

C2 - 28582280

AN - SCOPUS:85020204433

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

ER -